


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER
AND
APPOINTMENT OF CHIEF EXECUTIVE OFFICER**

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that Mr. Li Yi (“**Mr. Li**”) has resigned as an executive director and the Chief Executive Officer of the Company, as he wishes to focus on other business development, with effect from 28 July 2022. Mr. Li will be engaged as a senior consultant of the Company on the same date.

Mr. Li confirmed that he has no disagreement with the Board and that there are no matters which need to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board further announces that with effect from 28 July 2022, Mr. Tse, Eric S Y (“**Mr. Tse**”) has been appointed as the Chief Executive Officer of the Company.

Mr. Tse is an executive director and a substantial shareholder of the Company. The biographical details of Mr. Tse and his relationship with any directors, substantial or controlling shareholders and senior management of the Company, if any, can be found in the 2021 annual report of the Company. He did not hold any directorship in other listed companies in the past three years.

As at the date of this announcement, Mr. Tse, through companies wholly owned by him, holds shares of the Company representing approximately 21.53% in aggregate of the issued share capital of the Company. Apart from this, Mr. Tse does not have any interest or short position in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Tse has not entered into a service contract with the Company. Mr. Tse is not appointed for a specific term. The remuneration to be received by him in 2022 will be determined by the Board based on the Company's remuneration policy and with reference to his qualification and experience, responsibilities undertaken, contribution to the Company, and prevailing market level of remuneration of similar position.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

Continuously optimising the organisational structure, improving the management efficiency, promoting the modernisation of management system and deepening the talent strategy

After careful discussion, the Board of Sino Biopharm decided to respect Mr. Li Yi's personal wishes and thanked him for his positive efforts and contributions to the Company. Over the past two years, Mr. Li has brought to the Company useful experience in capital operations, and has effectively enhanced the overall effectiveness of the Group through the sorting out of strategies. In the next stage, Mr. Li will be re-designated as a senior consultant of the Company. The Board believes that Mr. Li would use his rich experience in global financial investment to help the Company's business internationalization development, and to provide the Company with effective recommendations on the formulation of corporate, investment and financing strategies.

While continuing to optimise its organizational structure, improve management efficiency and promote the modernization of its management system, Sino Biopharm will also deepen its talent strategy and recruit more outstanding professional managers, so as to make great strides towards its goal of being one of the "Top 30 Global Pharmaceutical Companies".

Mr. Tse, Eric S Y, the new Chief Executive Officer, has been serving as a director of Chia Tai – Tianqing Pharmaceutical Group Co. Ltd. ("**CT Tianqing**") since 2019 and the president of CT Tianqing since July 2020. Under the leadership of Mr. Tse, CT Tianqing has continued to promote the three strategies of "Comprehensive Innovation, Digital Transformation and Talent Strategy", with many achievements have been made. In terms of innovation and research and development ("**R&D**"), through its two-wheeled approach of independent R&D and in-depth collaboration, CT Tianqing has procured business development of a number of blockbuster innovative drugs through collaboration, and achieved a qualitative breakthrough in its own innovation transformation with increasing share of innovative drugs in its independent R&D pipeline and significant growth in revenue contribution from innovative drugs, which resulted in comprehensive acceleration in internationalization layout and steady growth

in performance. At the same time, CT Tianqing actively promotes corporate digital transformation to achieve lean operations, efficiency enhancement and quick adaptability to environmental changes. In terms of talent strategy, CT Tianqing vigorously promotes the optimization of its organisation and talent resources by bringing in domestic and overseas management teams, nurturing internal core talents, taking stock of internal talents, and establishing an equity incentive mechanism so as to secure a source of momentum for the organization's development.

After taking over as Chief Executive Officer, Mr. Tse will be responsible for the day-to-day business activities and the decision-making on major issues including corporate strategy, appointment and removal of personnel, and investment and integration, around Sino Biopharm's four key strategies of "Integration, Innovation, Globalization and Digitalization"; the overall management of the Company's subsidiaries; and the establishment of professional management teams to further enhance organizational efficiency, drive business innovation, connect with external collaboration, and promote innovation at a global level.

The new management will closely follow the four core strategic directions of Sino Biopharm to strengthen its business, of which, Ms. Tse, Theresa Y Y, the chairwoman of the Board, will focus on the strategic planning, international business, capital market operations of the Group and the listed company-related matters, while Mr. Tse, Eric S Y, the Chief Executive Officer, will focus on the operations management, organizational optimization and efficiency enhancement of all subsidiaries under the listed company. With their respective roles, the chairwoman of the Board and the Chief Executive Officer will lead Sino Biopharm's drive to innovate and continue to create value for patients, shareholders and the society.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 July 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan, Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.